Group 1 - The company has received the approval notice for the listing application of the chemical raw material drug Difluprednate from the National Medical Products Administration (NMPA) [1][3] - Difluprednate is a topical corticosteroid used to suppress inflammation caused by various irritants, primarily available in the form of eye drops for treating inflammation and pain related to eye surgeries [2][3] - The global sales figures for Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024, indicating a potential market opportunity for the company [3] Group 2 - The approval of the raw material drug will enhance the company's product portfolio and leverage its integrated advantages in raw material and formulation production, aiding in business expansion [4] - The company has invested approximately 2.6 million yuan in the research and development of the Difluprednate raw material project [3]

津药药业公告，近日收到国家药品监督管理局核准签发的二氟泼尼酯《化学原料药上市申请批准通知 书》。二氟泼尼酯属于局部用皮质激素药物，可抑制多种刺激性物质引起的炎症反应。目前市场上剂型 主要为滴眼液，主要用于治疗眼部手术相关的炎症和疼痛。根据IQVIA数据库显示，2023年、2024年二 氟泼尼酯制剂全球销售额分别为0.49亿美元、0.41亿美元。 ...